Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?

Diabetes and Metabolism

Volumn 29, Issue 5, 2003, Pages 470-476

  Cosson, E ^a,c   Guimfack, M ^a   Paries, J ^a   Paycha, F ^b   Attali, J R ^a   Valensi, P ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c HÔPITAL JEAN VERDIER   (France)

Author keywords

Coronary artery disease; Diabetes mellitus; Prognosis; Silent coronary stenosis; Silent myocardial ischemia

Indexed keywords

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DIABETES MELLITUS; ELECTROCARDIOGRAM; EXERCISE; FEMALE; GANGRENE; HEART ARRHYTHMIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PROGNOSIS; REVASCULARIZATION; RISK FACTOR; SURGICAL TECHNIQUE;

EID: 0344442364     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70060-5     Document Type: Article

References (27)

1. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Reviews, 1997, 5, 294-315.
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA, 1979, 241, 2035-8.
3. Stamler J, Vaccaro O, Neaton ID, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 1993, 16, 434-4.
4. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation, 1999, 100, 1134-46.
5. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care, 2001, 24, 339-43.
6. Valensi P, Sachs RN, Lormeau B, et al. Silent myocardial ischaemia and left ventricle hypertrophy in diabetic patients. Diabetes Metab, 1997, 23, 409-16.
7. Koistinen MI. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. BMJ, 1990, 301, 92-95.
8. Naka M, Hiramatsu K, Aizawa T, et al. Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart 1992, 123, 46-53.
9. Janned-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes. Who to screen. Diabetes Care, 1999, 22, 1396-400.
10. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Prevalence of unrecognized silent myocardial ischaemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol, 1997, 79, 134-9.
11. Haffner SM, Lehto S, Rönnemaa T, Pyöralä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339, 229-34.
12. Cohn P. Should silent ischemia be treated in asymptomatic individuals? Circulation, 1990, 82, 149-54.
13. Rutter M, Wahid S, McComb J, Marshall S. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol, 2002, 40, 56-61.
14. Vanzetto G, Halimi S, Hammoud T, et al. Prediction of cardiovascular events in clinically, selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care, 1999, 22, 19-26.
15. Faglia E, Favales F, Calia P, et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease. 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). Diabetes Care, 2002, 25, 2032-6.
16. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care, 2003, 26, 1313-4.
17. Guidelines for cardiac exercise testing. ESC Working Group on Exercise Physiology, Physiopathology and Electrocardiography. Eur Heart J, 1993, 14, 969-88.
18. Strauss HW, Miller DD, Wittry MD, et al. Society of Nuclear Medicine procedure guideline for myocardial perfusion imaging. In Society of nuclear medicine procedure guidelines manual. Society of Nuclear Medicine, 1997, Ed, Reston, Virginia, 1-14.
19. Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year (or patients with asymptomatic cardiac ischemia randomized to medical therapy of revascularization. The ACIP Investigators. J Am Coll Cardiol, 1995, 26, 594-605.
20. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation, 1999, 100, 2477-84.
21. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. J Am Coll Cardiol, 1995, 25, 619-25.
22. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet, 2000, 355, 253-9.
23. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation, 1998, 98, 2513-9.
24. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guideline. Arch Intern Med, 2003, 163, 33-40.
25. Strategies for care of the type 2 diabetic patient excluding care of complications. Recommendations of ANAES (National Agency for Health Accreditation and Evaluation March 2000). Diabetes Metab, 2000, 26, 10-96.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. The Lancet, 2002, 360, 7-22.
27. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care, 2002, 25, S78-S79.